<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929394</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1447-STBSG</org_study_id>
    <secondary_id>2016-003535-38</secondary_id>
    <nct_id>NCT02929394</nct_id>
  </id_info>
  <brief_title>Trabectedin Maintenance Post 1st-line in STS</brief_title>
  <official_title>Maintenance Therapy With Trabectedin Versus Observation After First Line Treatment With Doxorubicin of Patients With Advanced or Metastatic Soft Tissue Sarcoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintenance therapy with trabectedin versus observation after first line treatment with&#xD;
      doxorubicin of patients with advanced or metastatic soft tissue sarcoma.&#xD;
&#xD;
      This is a prospective, multicenter, randomized, open label Phase III trial investigating&#xD;
      whether a maintenance treatment with trabectedin, as compared to the observational approach,&#xD;
      can prolong progression-free survival in patients with advanced, inoperable and/or metastatic&#xD;
      STS after response or stabilisation during first line treatment with doxorubicin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progression free survival will be estimated by the Kaplan-Meier method. The median survival&#xD;
      time and its associated 95% non-parametric CI will be provided. Rates at 3 month intervals&#xD;
      will be estimated using the log-log transformation of the Kaplan-Meier estimates and the&#xD;
      standard deviation of the Kaplan Meier estimate based on the Greenwood formula.&#xD;
&#xD;
      For the primary analysis, PFS from randomization will be compared between the two arms using&#xD;
      the score test from a Cox proportional hazards model adjusted for histology (stratification&#xD;
      factor). The corresponding estimate of the treatment effect (hazard ratio) and 95% CI will be&#xD;
      provided.&#xD;
&#xD;
      Secondary analyses include:&#xD;
&#xD;
        -  the primary comparison of PFS repeated using methods for interval-censored data to&#xD;
           adjust for deviations from the planned imaging scheduled, if any.&#xD;
&#xD;
        -  the above mentioned analyses performed for PFS measured from date of starting firstline&#xD;
           doxorubicin treatment.&#xD;
&#xD;
      Overall survival and time to second progression (PFS2) measured from randomization and from&#xD;
      starting firstline doxorubicin treatment will be estimated by the Kaplan-Meier method. The&#xD;
      median times and their associated 95% non-parametric CI will be calculated. Rates at 3 month&#xD;
      intervals will be estimated using the log-log transformation of the Kaplan-Meier estimates&#xD;
      and the standard deviation of the Kaplan Meier estimate based on the Greenwood formula. They&#xD;
      will be compared between the two arms using an adjusted Cox proportional hazards model; the&#xD;
      corresponding estimates of the hazard ratio and 95% CI will be provided. The above mentioned&#xD;
      PFS2 comparison will also be repeated using methods for interval-censored data.&#xD;
&#xD;
      The adverse events related to the treatment (excluding those declared not reasonably possibly&#xD;
      related to the treatment, but including those with relationship not assessable) will be&#xD;
      described in the safety population. Worst grade of the AEs will be tabulated. Whenever a&#xD;
      CTCAE code exists, the grade will be displayed according to that system, otherwise the values&#xD;
      will be coded in up to three categories as below lower limit of normal (LLN), within normal&#xD;
      range, and above upper limit of normal (ULN), as deemed appropriate.&#xD;
&#xD;
      The percentage of patients presenting severe treatment-related AE (grade ≥ 3), of patients&#xD;
      reported to have died of toxicity and of patients who stopped treatment due to toxicity will&#xD;
      be calculated and the 95% confidence interval will be presented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Actual">June 5, 2020</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>until 3/4 years after randomization of the first patient</time_frame>
    <description>The primary end-point is progression-free survival defined from randomization according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Common Toxicity Criteria CTCAE 4.0)</measure>
    <time_frame>until 3/4 years after randomization of the first patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until 3/4 years after randomization of the first patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second progression (PFS2)</measure>
    <time_frame>until 3/4 years after randomization of the first patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (QLQ-C30)</measure>
    <time_frame>until 3/4 years after randomization of the first patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Sarcoma, Soft Tissue</condition>
  <arm_group>
    <arm_group_label>investigational treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity</description>
    <arm_group_label>investigational treatment</arm_group_label>
    <other_name>Yondelis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Histologically proven locally advanced or metastatic high grade STS (excluding&#xD;
             histologies insensitive to chemotherapy such as ASPS, PECOMA subtypes)&#xD;
&#xD;
          -  Non-progressive disease (CR, PR or SD according to RECIST 1.1) after 6 cycles of&#xD;
             first-line chemotherapy with doxorubicin for advanced and/or metastatic malignant STS.&#xD;
&#xD;
          -  Interval from last dose of doxorubicin to start of treatment is maximum 6 weeks.&#xD;
&#xD;
          -  Prior neoadjuvant or adjuvant non-anthracycline-chemotherapy is allowed, provided that&#xD;
             the disease did not progress during neoadjuvant and/or adjuvant therapy or within 12&#xD;
             weeks after completion of the perioperative treatment.&#xD;
&#xD;
          -  Representative formalin fixed, paraffin embedded tumor blocks or 10 unstained tissue&#xD;
             slides, either from the primary tumor or a metastatic lesion, must be available for&#xD;
             histological central review. Histological central review is not required before&#xD;
             treatment start but it is mandatory to send unstained tumor slides (blocks optional)&#xD;
             at time of study entry. Local histopathological diagnosis will be accepted for entry&#xD;
             into this trial.&#xD;
&#xD;
        Age 18 years or older WHO performance status ≤ 1&#xD;
&#xD;
        Adequate bone marrow, liver and renal function and coagulation parameters:&#xD;
&#xD;
          -  neutrophils ≥ 1.5 x 109/L;&#xD;
&#xD;
          -  hemoglobin ≥ 9 g/dL (or ≥ 5.6 mmol/L). Blood transfusions or the administration of&#xD;
             hematopoietic growth factors are allowed to achieve these baseline values;&#xD;
&#xD;
          -  platelets ≥ 100 x 109/L;&#xD;
&#xD;
          -  Total bilirubin ≤ ULN;&#xD;
&#xD;
          -  Albumin &gt; 30g/L&#xD;
&#xD;
          -  SGPT/ALT and SGOT/AST ≤ 2.5 x ULN for patients with liver metastasis or patients with&#xD;
             Gilbert syndrome bilirubin ≤ ULN;&#xD;
&#xD;
          -  Creatine phosphokinase (CPK) ≤ 2.5 x ULN;&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN (consider hepatic isoenzymes 5-nucleotidase or gamma&#xD;
             glutamyl transpeptidase (GGT), if the elevation could be osseous in origin);&#xD;
             Creatinine clearance/eGFR &gt;30mL/minmin as per local standard method&#xD;
&#xD;
          -  Normal cardiac function (LVEF assessed by MUGA or ECHO within normal range of the&#xD;
             institution), normal 12 lead ECG (without clinically significant abnormalities). The&#xD;
             following unstable cardiac conditions are not allowed:&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Angina pectoris&#xD;
&#xD;
          -  Myocardial infarction within 1 year before registration/randomization&#xD;
&#xD;
          -  Uncontrolled arterial hypertension defined as blood pressure ≥ 150/100 mm Hg despite&#xD;
             optimal medical therapy&#xD;
&#xD;
          -  Arrhythmias clinically significant&#xD;
&#xD;
          -  No prior exposure to trabectedin&#xD;
&#xD;
          -  Recovery from toxicity (no more than Grade 1, except for alopecia)&#xD;
&#xD;
          -  No active or uncontrolled infections or serious illnesses or medical conditions,&#xD;
             including a history of chronic alcohol abuse, hepatitis, HIV and/or cirrhosis.&#xD;
&#xD;
          -  No active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment&#xD;
             with radiotherapy, symptomatic, requiring treatment with anti-convulsants;&#xD;
             dexamethasone therapy is allowed if administered as stable dose for at least one month&#xD;
             before randomization)&#xD;
&#xD;
          -  No history, within the past five years, of malignancies other than soft tissue sarcoma&#xD;
             (except: basal or squamous cell carcinoma of the skin, in situ carcinoma of the&#xD;
             cervix, resected incidental prostate cancer staged pT2 with Gleason Score 6 and&#xD;
             postoperative PSA &lt; 0.5 ng/ml). Patients with any history of malignancies who are&#xD;
             disease-free for more than 5 years are eligible.&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 72 hours prior to the first dose of study treatment.&#xD;
&#xD;
          -  Patients of childbearing / reproductive potential should use adequate birth control&#xD;
             measures, as defined by the investigator, during the study treatment period and for at&#xD;
             least 3 months after the last study treatment. A highly effective method of birth&#xD;
             control is defined as those which result in low failure rate (i.e. less than 1% per&#xD;
             year) when used consistently and correctly.&#xD;
&#xD;
          -  Female patients who are breast feeding should discontinue nursing prior to the first&#xD;
             dose of study treatment.and until 3 months after the last study treatment.&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be given&#xD;
             according to ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Important note: All eligibility criteria must be adhered to, in case of deviation&#xD;
        discussion with Headquarters and study coordinator is mandatory.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Gelderblom</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsMedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>02 781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Chelsea, London</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histologically proven locally advanced or metastatic high grade STS (excluding histologies insensitive to chemotherapy such as ASPS, PECOMA subtypes)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All publications must comply with the terms specified in the EORTC Policy 009 &quot;Release of Results and Publication Policy&quot;.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

